Your browser doesn't support javascript.
Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population
iScience ; 2022.
Article in English | EuropePMC | ID: covidwho-2102742
ABSTRACT
This study aimed to determine the impact of ultra-rapid rollout vaccination on incidence of SARS-CoV-2 infection. Vaccination with BNT162b2 was provided to 66.9% of eligible residents of the Schwaz district in Tyrol, Austria, within six days per dose (first dose 11–16 March 2021, second dose 8–13 April 2021). Of 11,955 individuals enrolled at nine vaccination centers (median age 44.6 years;51.3% female), 71 had incident SARS-CoV-2 over a six-month follow-up. Incidence rates per 100,000 person-weeks were 92.3 (95% confidence interval [CI] 70.8–120.2) at weeks 1–5 and 6.4 (3.9–10.4) at ≥6 weeks after dose 1. In these two periods, effectiveness of the vaccination campaign to reduce incident SARS-CoV-2 was 58.6% (50.8%–65.2%) and 91.1% (89.6%–92.3%) in study participants and 28.3% (23.1%–33.0%) and 64.0% (61.7%–66.1%) in the Schwaz district, compared with districts with slower vaccination rollout. Therefore, the vaccination campaign in the Schwaz district illustrates the impact of accelerated vaccination rollout in controlling the pandemic. Graphical Health sciences;Population;Immunology
Search on Google
Collection: Databases of international organizations Database: EuropePMC Topics: Vaccines Language: English Journal: IScience Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: EuropePMC Topics: Vaccines Language: English Journal: IScience Year: 2022 Document Type: Article